Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;31 Suppl 1(Suppl 1):33-39.
doi: 10.1111/exd.14609.

New treatments and new assessment instruments for Hidradenitis suppurativa

Kelsey R van Straalen  1   2 , John R Ingram  2   3 , Matthias Augustin  2   4 , Christos C Zouboulis  2   5
Affiliations
Review

New treatments and new assessment instruments for Hidradenitis suppurativa

Kelsey R van Straalen et al. Exp Dermatol. 2022 Sep.

Abstract

Research interest in Hidradenitis Suppurativa (HS) has grown exponentially over the past decades. Several groups have worked to develop novel scores that address the drawbacks of existing investigator-assessed and patient-reported outcome measures currently used in HS trials, clinical practice and research. In clinical trial settings, the drawbacks of the HiSCR have become apparent; mainly, it is lack of a dynamic measurement of draining tunnels. The newly developed (dichotomous) IHS4 and HASI-R are backed up by adequate validation data and are good contenders to become the new primary outcome measure in HS clinical trials. Patient-reported outcomes, as well as physician reported measures, are being developed by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). For example, the Hidradenitis Suppurativa Quality of Life (HiSQOL) score is a validated measure of HS-specific quality of life and is already being used in many HS trials. Magnitude of pain measurement via a 0-10 numerical rating scale is well-established; however, consensus is still required to ensure consistent administration and interpretation of the instrument. A longitudinal measurement over multiple days rather than at one time point, such as for example the Pain Index could provide increased reliability and reduced recall bias. Ultimately, these newly developed scores and tools can be included in a standardized registry to be used in routine clinical practice.

Keywords: ERHS; HISTORIC; HiSCR; HiSQOL; IHS4; outcome measurement instruments; pain; pain index; patient-reported outcome measures; quality of life.

PubMed Disclaimer

Conflict of interest statement

All authors declare that none of the mentioned conflicts of interest had any influence to this manuscript. KRvS declares no conflicts of interest. JRI reports consultancy/advisory boards for Boehringer Ingelheim, ChemoCentryx, Insmed, Kymera Therapeutics, Novartis, UCB Pharma and Viela Bio. JRI is Treasurer of C3 (merger of CHORD & CS‐COUSIN), HISTORIC Steering Committee member and lead for HISTORIC Pain domain work group. He is co‐copyright holder of HiSQOL, Investigator Global Assessment and Patient Global Assessment for HS. JRI is BJD Editor‐in‐Chief and receives an authorship honorarium for two UpToDate HS chapters. MA reports consulting fees and/or research grants from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Hexal, Janssen, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, and UCB. CCZ reports consultancy/advisory boards disease‐relevant honoraria from AbbVie, Bayer, Incyte, Inflarx, Janssen, Novartis, Regeneron, and UCB. He has received speaker fees from AbbVie and UCB. CCZ is President of the EHSF e.V., coordinator of the ALLOCATE Skin group of the ERN Skin and chair of the ARHS Task Force group of the EADV. He is Editor of the EADV News. CCZ is co‐copyright holder of HIS4 on behalf of the EHSF e.V. His employer has received disease‐relevant grants from AbbVie, Boehringer‐Ingelheim, InflaRx, Novartis, and UCB for his participation as clinical investigator.

Figures

FIGURE 1
FIGURE 1
“Onion skin model” of the core outcome set for hidradenitis suppurativa (HS) clinical trials, showing domains and their constituent items. The left‐hand circle is the core domain set, with inclusion of the symptoms domain as well. Patient‐reported outcomes are highlighted in red. Reproduced with permission
See this image and copyright information in PMC

References

    1. Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6:18. - PubMed
    1. Ingram JR, Hadjieconomou S, Piguet V. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol. 2016;175:263‐272. - PubMed
    1. Kirby JS, Butt M, King T. Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa. Br J Dermatol. 2020;182:940‐948. - PMC - PubMed
    1. Goldfarb N, Ingram JR, Jemec GBE, et al. Hidradenitis Suppurativa Area and Severity Index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa. Br J Dermatol. 2020;182:240‐242. - PMC - PubMed
    1. Goldfarb N, Lowes MA, Butt M, King T, Alavi A, Kirby JS. Hidradenitis Suppurativa Area and Severity Index Revised (HASI‐R): psychometric property assessment. Br J Dermatol. 2021;184:905‐912. - PMC - PubMed

MeSH terms